Editorial

Discharge after TAVI: it can be fast

EuroIntervention 2019;15:131-133. DOI: 10.4244/EIJV15I2A25

Maarten van Wiechen
Maarten van Wiechen 1, MD; Joris F.W. Ooms 1, MD; Nicolas M. Van Mieghem 1, MD, PhD
1. Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands
Transcatheter aortic valve implantation (TAVI) can now be considered for any patient with symptomatic severe aortic stenosis (AS) who is set to receive an aortic valve replacement with a bioprosthesis1,2,3,4. In particular, the recent low-risk trials may dramatically increase the pool of eligible TAVI candidates, with estimates as high as 270,000 patients in Europe and North America5. The healthcare challenges for heart valve centres are significant. Different levels within a given TAVI programme require restructuring to cope with this changing supply/demand reality at reasonable cost and without concessions in quality. This includes: 1) stronger ties with referral hospitals to relocate preprocedural ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
FFR-guided PCI in STEMI

Latest news